{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-12T00:47:28.597Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"GEHC\",\n \"company\": \"GE HealthCare Technologies Inc.\",\n \"investigation_summary\": \"The investigation trigger was 7 Form 4 filings in 14 days, but on close inspection ALL were director RSU grants (code A) — not open-market purchases. One genuine CFO open-market purchase exists ($200K+ at $60.60 on May 1). The stock crashed ~13% on April 29 after a Q1 EPS miss and guidance cut driven by supply-chain cost inflation and a supplier quality recall in Pharma Diagnostics. Technicals are deeply oversold (RSI 35.5), forward P/E is compressed to 11.5x, analysts still target $80, and the stock sits ~31% below its 52-week high — creating an attractive covered-call income setup at elevated IV rather than a directional long.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 4,\n \"structure_hints\": [\n \"cc\",\n \"csp\"\n ],\n \"business_snapshot\": \"GE HealthCare is a ~$21B revenue medical imaging and diagnostics company spun from GE in January 2023. It operates four segments: Imaging (CT, MR, X-ray), Advanced Visualization Solutions (ultrasound, interventional), Patient Care Solutions (monitoring, life support), and Pharmaceutical Diagnostics (contrast agents). The company recently consolidated its Imaging and AVS units into a single 'Advanced Imaging Solutions' segment (~20% of revenue organic growth in Q1). Recent M&A includes Intelerad (March 2026) and icometrix (Nov 2025) for AI-enabled diagnostic software. Key risks are China exposure, tariff sensitivity on component sourcing, and a supplier quality recall affecting PDx — which drove the guidance cut.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [\n {\n \"insider\": \"James Saccaro\",\n \"role\": \"CFO\",\n \"amount_usd\": 200585,\n \"date\": \"2026-05-01\",\n \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1932393/000159363626000008/xslF345X06/wk-form4_1777649933.xml\"\n }\n ],\n \"insider_open_market_total_usd_90d\": 200585,\n \"distinct_insider_buyers_90d\": 1,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": true,\n \"material_insider_selling_90d_usd\": 0,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-07-29\",\n \"recent_eps_surprise_pattern\": \"-5.71% miss in Q1 2026 ($0.99 actual vs $1.05 est); prior three quarters beat by +2-15%\",\n \"guidance_raise_in_last_90d\": false,\n \"named_catalysts\": [\n {\n \"type\": \"earnings\",\n \"description\": \"Q2 2026 earnings with margin recovery commentary and full-year guidance update\",\n \"date_or_window\": \"2026-07-29\",\n \"source_urls\": [\n \"https://www.sec.gov/Archives/edgar/data/1932393/000193239326000030/gehc-20260429.htm\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"product\",\n \"description\": \"Phase 2/3 LUMINA trial data for manganese-based MRI contrast agent (non-GADOLINIUM alternative) — potential differentiation vs gadolinium safety concerns\",\n \"date_or_window\": \"H2 2026\",\n \"source_urls\": [],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"m&a\",\n \"description\": \"Intelerad acquisition closed March 2026, icometrix integrated — software/AI portfolio expansion into radiology PACS and brain imaging AI\",\n \"date_or_window\": \"Q1-Q2 2026\",\n \"source_urls\": [],\n \"directional_bias\": \"bullish\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": 11.47,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": 10.4,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": 6.12,\n \"sotp_gap_pct\": null,\n \"narrative\": \"Forward P/E of 11.5x is compressed vs sector medians (~18-20x for medical devices); analyst consensus target of $80 implies ~30% upside from current $61.70; FCF yield of ~6% is attractive if margins stabilize. The guidance cut caused mechanical selling (stock -13% in one day) without permanent impairment to competitive position.\"\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": null,\n \"net_debt_to_ebitda\": 4.1,\n \"balance_sheet_grade\": \"B+\"\n },\n \"technical\": {\n \"above_50dma\": false,\n \"above_200dma\": null,\n \"rsi_14\": 35.5,\n \"macd_recent_bullish_cross\": false,\n \"12_1_momentum_vs_sector_pct\": -26\n }\n },\n \"price_context\": {\n \"last_close\": 61.7,\n \"ytd_return_pct\": -13.83,\n \"from_52w_high_pct\": -31.3\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-K\",\n \"filed\": \"2026-02-04\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1932393/000193239326000007/gehc-20251231.htm\",\n \"key_takeaways\": [\n \"FY2025 revenue $19.5B; net income ~$1.9B; Imaging segment largest at ~47% of revenue; PDx recall noted as ongoing supplier quality issue; debt levels ~$10.6B vs $2.3B cash\"\n ]\n },\n {\n \"form\": \"10-Q\",\n \"filed\": \"2026-04-29\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1932393/000193239326000031/gehc-20260331.htm\",\n \"key_takeaways\": [\n \"Q1 2026: revenue $5.13B (+7.4% yoy) but EPS miss at $0.99 vs $1.05 est; gross margin compressed to 38.5%; operating income $515M vs $629M year ago due to input cost inflation and PDx recall; Intelerad acquired March 18, 2026\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-04-29\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1932393/000193239326000030/gehc-20260429.htm\",\n \"key_takeaways\": [\n \"Earnings release confirming Q1 miss and FY guidance reduction to reflect higher freight/sourcing costs and supplier quality issue in Pharma Diagnostics\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-05-29\",\n \"2026-06-12\"\n ],\n \"iv_summary\": \"ATM IV ~34-37% on near-term expirations; OTM calls (65-68 strike) show elevated skew suggesting premium available for CC strategies\",\n \"notable_skew_or_flow\": \"Jun 68C has OI of 53 contracts — open interest concentration at $68 level represents potential resistance; put/call ratio 0.20 with net call bias +70% dollar notional, confirming bullish flow from options participants\"\n },\n \"competitive_landscape\": \"GEHC competes in medical imaging with Siemens Healthineers (SHLSY), Philips (PHG), Canon Medical (CAJTY), and Intuitive Surgical (ISRG) for surgical robotics. In patient monitoring, Masimo (MASI) is a competitor. The company holds ~25-30% global market share in MRI and CT; competitive moat centers on installed base (recuring service revenue), GE brand recognition in emerging markets, and AI-enabled software (MIM Software, icometrix, Intelerad). Differentiation vs Siemens Healthineers is primarily price/emerging-market reach rather than technology leadership.\",\n \"key_risks\": [\n \"Tariff escalation on China-sourced components could further pressure margins — company notes 'tariffs and inflation' as ongoing headwind in April AGM remarks\",\n \"PDx supplier quality issue not fully resolved; potential for additional recall costs and revenue impact at next earnings\",\n \"Earnings growth is negative YoY (-30.9% earnings decline TTM) — stock screens cheap but only if margin pressure reverses\",\n \"High debt-to-equity (97%) creates refinancing risk in elevated rate environment\",\n \"China regulatory and geopolitical risk — significant revenue exposure to Chinese hospitals and government tenders\"\n ],\n \"what_the_market_might_be_missing\": \"The Q1 miss was driven by one-time supply-chain cost inflation and a discrete PDx recall event — not structural demand destruction. Revenue actually beat, imaging backlog remains robust (company cited strong commercial performance), and the MIM/icometrix/Intelerad software acquisitions expand recurring revenue. At 11.5x forward P/E vs historical average of ~18-20x for this quality of franchise, there's a mean-reversion case — but only if margins stabilize at next earnings (July 29). The CFO buying at $60.60 (vs current $61.70) is a thin signal but not meaningless.\",\n \"anti_signals_present\": [\n \"dilution\",\n \"concentration\"\n ],\n \"sources\": [\n {\n \"label\": \"Form 4 - CFO open-market purchase May 1 2026\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1932393/000159363626000008/xslF345X06/wk-form4_1777649933.xml\"\n },\n {\n \"label\": \"Q1 2026 earnings 8-K / press release context\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1932393/000193239326000030/gehc-20260429.htm\"\n },\n {\n \"label\": \"Q1 2026 10-Q (revenue/margin data)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1932393/000193239326000031/gehc-20260331.htm\"\n },\n {\n \"label\": \"Fundamentals snapshot\",\n \"url\": \"\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-12T00:48:15.631Z", "raw_content": "The user wants me to score the dossier for GEHC and decide whether to skip or draft an idea.\nI need to follow the scoring rubric, check risk class, thresholds, anti-signal gates, and edge check.\nThen output the decision JSON.\n\nLet's score step-by-step:\n\nA. SMART-MONEY CLUSTER (max 25)\n- 10 pts if 3+ distinct insiders with open-market purchases (code P) in last 90 days totaling ≥ $500K -> Only 1 insider (CFO) bought $200K. So 0 pts.\n- +3 pts if CEO is among the buyers -> No\n- +3 pts if CFO is among the buyers -> Yes, +3\n- +2 pts if total purchases > $5M -> No\n- 5 pts for a known concentrated 13F initiation/add -> \"pending — v2\" -> 0\n- +3 pts if it's in the manager's top-3 positions -> 0\n- 2 pts for politician STOCK Act recent buy -> \"pending — v2\" -> 0\n- +1 pt if multiple unrelated members bought within 30 days -> 0\n- Penalty: −10 pts if material insider SELLING > BUYING -> 0\nScore A: 3\n\nB. OPTIONS FLOW / UOA (max 10)\n- 4 pts: whale_call_blocks_otm ≥ 2 -> Not mentioned. 0\n- 3 pts: bullish IV skew -> \"ATM IV ~34-37% on near-term expirations; OTM calls (65-68 strike) show elevated skew\" -> 3\n- 2 pts: net_dollar_bias_pct > 30 -> \"put/call ratio 0.20 with net call bias +70% dollar notional\" -> 2\n- 1 pt: large OI building at a defended price level -> \"Jun 68C has OI of 53 contracts\" -> 1\n- Penalty: -5 if put blocks -> 0\nScore B: 6\n\nC. CATALYST (max 25)\n- 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0% -> Next earnings 2026-07-29. Last 4 quarters pattern: \"-5.71% miss in Q1 2026; prior three quarters beat\". So not all > 0%. 0 pts.\n- 8 pts: pending product launch / FDA / contract milestone -> LUMINA trial data H2 2026. Too far. 0\n- 5 pts: recent guidance raise -> false. 0\n- 5 pts: quantifiable sector tailwind -> 0\nScore C: 0 (Maybe 0 or very low. Wait, earnings is within 90 days but missed the EPS surprise condition. I'll give 0.)\n\nD. MISPRICING (max 15)\n- 5 pts: forward P/E ≥ 20% below sector median -> Forward P/E 11.47 vs sector ~18-20x. That's ~35-40% below. +5\n- 4 pts: EV/EBITDA ≥ 30% below sector median -> EV/EBITDA 10.4 vs sector (implied higher for med devices). Let's assume it's below, but sector median is null. I'll give 0 to be safe, or 4 if plausible. The narrative says \"compressed vs sector medians (~18-20x for medical devices)\". So P/E is the main one. I'll give 5.\n- 4 pts: FCF yield ≥ 7% -> 6.12%. 0\n- 5 pts: SOTP gap ≥ 25% -> null. 0\nScore D: 5\n\nE. QUALITY (max 15)\n- 5 pts: ROIC ≥ 15% -> null. 0\n- 5 pts: gross margin expanding ≥ 3pp YoY -> gross margin compressed to 38.5%. 0\n- 5 pts: net debt / EBITDA ≤ 2x -> 4.1. 0\nScore E: 0\n\nF. MOMENTUM/TECHNICAL (max 10)\n- 3 pts: above both 50DMA and 200DMA -> false/null. 0\n- 4 pts: 12-1 month price return positive AND beating sector -> -26% vs sector. 0\n- 2 pts: RSI 14 in 40-65 zone -> 35.5. 0\n- 1 pt: MACD bullish cross -> false. 0\nScore F: 0\n\nTotal Score: 3 + 6 + 0 + 5 + 0 + 0 = 14.\nThis is very low.\n\nCheck Anti-Signals:\n\"anti_signals_present\": [\"dilution\", \"concentration\"]\nThe prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nDilution and concentration are red flags. Also, the dossier mentions high debt ($10.6B vs $2.3B cash), margin compression, tariff risk, and China exposure.\nThe score is 14, well below any threshold.\nRisk class: market_cap is not explicitly given, but revenue is ~$21B, so likely >$5B (core). Even if asymmetric, score < 60.\nVerdict: range_bound_or_income. But score is too low to justify even an income trade given the quality issues, margin compression, and anti-signals.\nEdge check: \"The Q1 miss was driven by one-time supply-chain cost inflation and a discrete PDx recall event — not structural demand destruction.\" But margins are compressing, debt is high, and there's no strong catalyst or insider buying cluster. The market is likely pricing in real margin pressure and execution risk. Generic \"cheap\" argument.\n\nI will skip.\nScore breakdown:\nsmart_money: 3\noptions_flow: 6\ncatalyst: 0\nmispricing: 5\nquality: 0\ntechnical: 0\nTotal: 14\nReason: Scored 14/100 due to lack of insider conviction, negative quality/momentum metrics, and active anti-signal gates (dilution, concentration). The \"cheap\" valuation is offset by real margin compression and high leverage, making even an income structure too risky without a clearer catalyst or margin stabilization signal.\n\nCheck thresholds: Core < 50 skip. Asymmetric < 60 skip.\nOutput matches skip format.\nI will produce the JSON.\nDouble check scoring:\nA: CFO buy = +3. Total 3.\nB: IV skew +3, net call bias +2, OI level +1 = 6.\nC: 0.\nD: P/E discount = 5.\nE: 0.\nF: 0.\nTotal 14.\nMatches.\nReady. \nOutput matches requested format exactly.\nNo extra text.\nProceeds. \nOne minor thing: The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will mention this in the reason.\nAll good. \nOutput generation. \n{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 3,\n \"options_flow\": 6,\n \"catalyst\": 0,\n \"mispricing\": 5,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Scored 14/100 due to weak insider conviction, deteriorating quality metrics (margin compression, 4.1x net debt/EBITDA), and active anti-signal gates (dilution, customer concentration). The compressed valuation is a value trap rather than a mispricing, as margin pressure and execution risks remain unresolved ahead of the July earnings date.\"\n}\nMatches schema. Done. \nSelf-Correction/Verification during thought:\nWait, let's verify the scoring rubric for A: \"10 pts if 3+ distinct insiders... +3 pts if CFO is among the buyers\". So max for A is 3. Correct.\nB: IV skew 3, net bias 2, OI 1 = 6. Correct.\nC: 0. Correct.\nD: 5. Correct.\nE: 0. Correct.\nF: 0. Correct.\nTotal 14.\nAnti-signals: dilution, concentration. I'll note them.\nThe output format requires exactly the JSON.\nProceeds. \nAll good. \nOutput matches. \nDone. \n[Output Generation] -> JSON string. \nNote: I will ensure the JSON is valid and strictly follows the schema.\nThe prompt asks for \"ONLY ONE STRUCTURE TYPE\" but since I'm skipping, I just output the skip object.\nReady. \nProceeds. \n{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 3,\n \"options_flow\": 6,\n \"catalyst\": 0,\n \"mispricing\": 5,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Scored 14/100 due to weak insider conviction, deteriorating quality metrics (margin compression, 4.1x net debt/EBITDA), and active anti-signal gates (dilution, concentration). The compressed valuation reflects real execution and margin risks rather than a market mispricing, making even an income structure too risky without clearer stabilization signals.\"\n}\nLooks solid. Matches all constraints. Output matches. \nProceeds. \n(Self-Correction/Refinement during thought)\nWait, let's check the scoring rubric for A again: \"10 pts if 3+ distinct insiders... +3 pts if CEO is among the buyers +3 pts if CFO is among the buyers\". It doesn't say the +3 is conditional on the 10 pts. It's additive. So +3 for CFO is correct.\nB: \"3 pts: bullish IV skew... 2 pts: net_dollar_bias_pct > 30... 1 pt: large OI building\". All apply. Total 6.\nD: \"5 pts: forward P/E ≥ 20% below sector median\". 11.47 vs ~18-20 is >20% below. +5.\nTotal 14. Correct.\nAnti-signals present: dilution, concentration. I will mention them.\nEverything is consistent.\nOutput matches.\nDone. \nProceeds. \n[Final Check of the Prompt]\n\"IF YOU SKIP — output exactly: { \"skip\": true, \"score\": ..., \"score_breakdown\": ..., \"reason\": ... }\"\nAll good.\nOutput matches.\nDone. \n[Output Generation] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 3,\n \"options_flow\": 6,\n \"catalyst\": 0,\n \"mispricing\": 5,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Scored 14/100 due to weak insider conviction, deteriorating quality metrics (margin compression, 4.1x net debt/EBITDA), and active anti-signal gates (dilution, concentration). The compressed valuation reflects real execution and margin risks rather than a market mispricing, making even an income structure too risky without clearer stabilization signals.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 3,\n \"options_flow\": 6,\n \"catalyst\": 0,\n \"mispricing\": 5,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Scored 14/100 due to weak insider conviction, deteriorating quality metrics (margin compression, 4.1x net debt/EBITDA), and active anti-signal gates (dilution, concentration). The compressed valuation reflects real execution and margin risks rather than a market mispricing, making even an income structure too risky without clearer stabilization signals.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 3,\n \"options_flow\": 6,\n \"catalyst\": 0,\n \"mispricing\": 5,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Scored 14/100 due to weak insider conviction, deteriorating quality metrics (margin compression, 4.1x net debt/EBITDA), and active anti-signal gates (dilution, concentration). The compressed valuation reflects real execution and margin risks rather than a market mispricing, making even an income structure too risky without clearer stabilization signals.\"\n}", "tool_calls_total": 0, "walltime_ms": 47035, "stop_reason": "stop", "completed_at": "2026-05-12T00:48:15.632Z" }